KRASG12C

Overview

KRASG12C refers to a specific oncogenic variant of the KRAS gene, defined by a glycine-to-cysteine substitution at codon 12. This mutation is clinically important because it creates a druggable cysteine residue that has enabled the development of mutation-selective KRAS inhibitors. In cancer biology, KRASG12C is most prominently associated with solid tumors such as non-small-cell lung cancer (NSCLC) and lung adenocarcinoma (LUAD), and it is also relevant in pancreatic cancer research.

Biologically, KRAS is a central signaling node that regulates pathways involved in cell growth and survival, including downstream MAPK signaling. In KRASG12C-mutant tumors, constitutive oncogenic signaling drives malignant proliferation and therapeutic resistance. The emergence of KRASG12C inhibitors has represented a major advance in targeted oncology, but resistance remains a significant challenge, motivating ongoing research into combination strategies and resistance mechanisms involving pathways such as FGF2-PI3K-Akt1 signaling and MAPK1-related signaling outputs.

Recent Publications Focus

Below is a summary of the newest research publications targeting KRASG12C (sorted by publication date).

Recent studies have continued to expand the therapeutic landscape around KRASG12C, with conference coverage highlighting irreversible KRASG12C inhibitors as an active area of oncology development. In parallel, preclinical and translational work has focused on combination strategies and resistance biology, reflecting the persistent challenge of durable responses to direct KRASG12C targeting.

Several publications examined mechanisms of resistance to KRASG12C inhibition. In a multi-omics study of resistant models, ATF3-mediated asparagine biosynthesis emerged as a key convergence point of acquired resistance, with chronic integrated stress response activation driving ATF3 upregulation and ASNS transactivation; genetic or pharmacologic disruption of this axis restored sensitivity, and PERK inhibition synergized with KRASG12C inhibitors. Another study of patients treated with glecirasib (JAB-21822) found that circulating tumor cell dynamics tracked treatment response and progression in gastrointestinal tumors harboring KRASG12C mutations, with baseline and on-treatment CTC subtypes associated with progression-free and overall survival, and local radiotherapy after progression linked to longer survival in patients with elevated CTC counts.

Other recent work explored ways to improve KRASG12C-directed therapy or exploit Kras pathway dependencies. A structure-based drug discovery effort identified potent SOS1 inhibitors that disrupted the SOS1-KRASG12C interaction, inhibited nucleotide exchange across Kras variants, suppressed MAPK and PI3K signaling, and reduced tumor growth in colorectal cancer xenografts without significant toxicity. In pancreatic cancer cell models harboring KRASG12C and KRASG12D, an active fragment assembly approach yielded a Kras inhibitor candidate that reduced phosphorylated Raf1, AKT, and ERK and showed selective antiproliferative activity. Together, these studies underscore KRASG12C as both a direct therapeutic target and a focal point for resistance mechanisms, biomarker development, and combination strategy design.

Background PMIDs

• [PMID 41926959]
• [PMID 42405535]
• [PMID 42407377]

Target PMIDs

• [PMID 41931988]
• [PMID 42200804]
• [PMID 42247371]
• [PMID 42270775]
• [PMID 42384131]
• [PMID 42388021]
• [PMID 42406708]